Other names: peginterferon beta 1a
You self-inject Plegridy under the skin once every two weeks to reduce the number and severity of relapses. It reduces the number of relapses by about one third (30%), compared to taking placebo.
Common side effects include flu-like symptoms and injection site reactions.
What is Plegridy used for in MS?
Plegridy is a moderately effective (category 1.1) DMD; in clinical trials people taking Plegridy had about 30% fewer relapses than people taking placebo. In clinical trials, MRI scans showed people taking Plegridy had fewer, smaller or no new areas of active MS (lesions). Plegridy may also slow down the build-up of disability associated with MS.
Who can take Plegridy?
Plegridy can be prescribed for adults with relapsing remitting MS.
Plegridy has been approved for use on the NHS since 2015. It can only be prescribed by a neurologist.
It's important that you tell your MS team if you have any health problems or are taking other medicines. Plegridy may not be suitable if you have severe depression or suicidal thoughts.
Conception and pregnancy
Do not start taking Plegridy if you are already pregnant. If you are planning to become pregnant or you become pregnant while taking Plegridy, tell your neurologist or MS team. You can then discuss with your doctor if you should carry on taking it.
How do I take Plegridy?
You self-inject Plegridy under the skin once every two weeks. Plegridy is supplied in single-use, pre-filled injection pens.
Your MS nurse will show you how to do the injections, discuss the practicalities and offer advice or training and ongoing support if you should need it.
To give your body a chance to get used to Plegridy and reduce the impact of side effects, you start on low doses for the first two injections, increasing to the full dose with the third injection.
What side effects could I get with Plegridy?
Common side effects include:
- Flu-like symptoms, such as headache, muscle ache and stiffness, chills or fever, following an injection
- Injection site reactions
You are more likely to have these side effects when you first start taking Plegridy. Most people have mild to moderate side effects which tend to go away over time.
A neurologist or MS specialist nurse may suggest ways to reduce these side effects including:
- To help with flu-like symptoms, it may be helpful to change the time of day of injection in order to sleep through the worst of the side effects
- To help reduce fever, paracetamol or ibuprofen can be taken before the injection and at four to six hour intervals after the injection, as required
Common side effects (affecting more than 1 person in 100)
- flu-like symptoms
- injection site reactions
- blood cell abnormalities
- feeling weak or tired
- difficulty sleeping
- diarrhoea, nausea and vomiting
- muscular or joint pain
Less common side effects (affecting less than 1 person in 100)
- changes in menstruation (periods)
- neurological symptoms, mood changes, depression
- liver abnormalities
- allergic reactions
- heart problems and hypertension
- damage to small blood vessels leading to kidney problems
A full list of side effects is included in the manufacturer's Patient Information Leaflet.
Assessment before treatment
Before starting Plegridy, you should have blood tests to measure blood cell counts and check liver function.
Assessment during treatment
Once you've started treatment, you'll have blood tests to measure blood cell counts and monitor liver function, generally every three months for the first year, then less frequently. Depending on local practice, the tests may be carried out at a local GP surgery or it may be necessary to attend a hospital clinic. You may also have tests of your thyroid function.
How does Plegridy work?
Interferons are proteins that occur naturally in the immune system . It is thought that beta interferon acts by reducing both inflammation and the immune response that is attacking the body's own myelin. Plegridy is formed by adding polyethylene glycol to interferon beta 1a, which maintains the effect of the drug in the body for longer.
One large study has provided evidence to support the approval of Plegridy for multiple sclerosis:
ADVANCE - Plegridy compared to placebo
This two year study compared Plegridy taken by injection once every two weeks or once every four weeks with placebo in 1,512 people. At the end of the first year, Plegridy reduced the relapse rate by 35.6% in the two weekly dosing group compared to placebo. Plegridy also reduced the number of brain lesions on MRI and the risk of worsening disability.
- Full guideline Advice: peginterferon beta 1a (Plegridy)
- Full guideline Appraisal information: peginterferon beta 1a (Plegridy)
- Lancet Neurology 2014;13:657-65. Summary Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
- Multiple Sclerosis 2015;21(8): 1025–1035. Full article Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE.
Compare Disease Modifying Drugs
Use our MS Decisions aid to help filter and compare the different types of disease modifying drugs (DMDs) that are available to treat relapsing MS.
It is only with the help of our donors, supporters and volunteers that we can continue training MS specialists, funding vital research and providing trusted information to the 100,000 people living with MS across the UK.
Questions about MS?
0800 032 3839
Open Monday to Friday, 9am - 5pm.